Actelion Ltd.
is a leading
biopharmaceutical
company focused
on the discovery,
development
and commercialization
of innovative drugs
for diseases
with significant
unmet medical needs.

Actelion presented at J. P. Morgan 2015

Jean-Paul Clozel, CEO, presented at the
J. P. Morgan Healthcare Conference, describing
the progress made during 2014 in delivering on
Actelion's strategy for value creation.

Jean-Paul Clozel, CEO, presented at the
J. P. Morgan Healthcare Conference, describing
the progress made during 2014 in delivering on
Actelion's strategy for value creation.

Global Actelion

Hotspot of possibilities

Actelion has subsidaries in over 30 countries, covering all major pharmaceutical markets worldwide

Hotspot of possibilities

Actelion has subsidaries in over 30 countries, covering all major pharmaceutical markets worldwide

Shareprice

ATLN SIX Swiss Exchange

Shareprice
At 17:30:46 CET 23/01/2015
CHF 96,95Up Down image
+3,45 (+3,69%)